$10M for SBIR Phase IIB Bridge Awards Now Available

Application Deadlines: November 6, 2012 & March 6, 2013

Are you looking for funding to commercialize your SBIR Phase II project? The National Cancer Institute Small Business Innovation Research (NCI SBIR) Development Center has announced $10M in funding through the FY2013 SBIR Phase IIB Bridge Award, designed to support the next stage of development for promising NIH-funded SBIR Phase II projects advancing cancer research technologies. The NCI intends to fund up to ten new awards for small businesses working in cancer therapeutics, imaging technologies, interventional devices, or diagnostics and prognostics.

 

The Phase IIB Bridge Award helps to:

  • “Bridge” the funding gap, known as the “Valley of Death,” between the end of the SBIR Phase II award and the subsequent round of financing needed to advance a promising product or service toward commercialization.
  • Incentivize partnerships between NIH’s SBIR Phase II awardees and third-party investors or strategic partners.

Budgets up to $1 million in total costs per year and project periods up to three years (a total of $3 million over three years) may be requested from the NCI. Development efforts may include preclinical R&D needed for regulatory filings (e.g., IND or IDE) or clinical trials. NCI intends to commit $10M for up to 10 new awards in FY2013.

For information on how to apply, please review the Funding Opportunity Announcement (FOA) at: http://grants.nih.gov/grants/guide/rfa-files/RFA-CA-12-023.html

Competitive preference and funding priority will be given to applications deemed likely to result in a commercial product as indicated by the applicant’s ability to secure substantial independent third-party investor funds (i.e. third-party funds that equal or exceed the requested NCI funds). Examples of third-party investors include drug or device manufacturers, angel investors, venture capital investors, state investment funds, foundations, and universities. Applicants must provide a commercialization plan that describes the long-term commercialization strategy and details on any independent third-party investor funding that has already been secured or will be provided during the Bridge Award project period.

Eligibility

  • The SBIR Phase IIB Bridge Award funding opportunity is open to NIH SBIR Phase II projects nearing completion and those that have recently ended.
  • Applications may be predicated on a previously funded SBIR Phase II grant or contract award.*
  • To be eligible under the current FOA, current Phase II projects MUST end on or before August 31, 2013, and not more than 24 months prior to the application receipt date (NCI will consider longer periods of hiatus on a case-by-case basis).

The deadlines to submit an FY2013 SBIR Phase IIB Bridge Award are November 6, 2012 & March 6, 2013.

We encourage you to learn more about this opportunity and apply!

*NOTE: Applicants who intend to submit a Phase IIB Bridge Award application that is predicated on an SBIR Phase II contract MUST contact the SBIR Development Center prior to submission, so that NCI can properly arrange for such applications to be accepted.

 

Learn about SBIR Phase IIB Bridge Awardees
Read about current NCI SBIR Bridge Awardees and the cancer technologies they are developing to improve detection and treatment for clinical use.

Announcements from NIH: Resources for Small Business Applicants

NIH offers a number of resources beyond funding that are available to small businesses. Two programs have upcoming deadlines:

  • NIH Niche Assessment Program for SBIR & STTR Phase I Awardees: NIH recently announced the 9th year of the Niche Assessment Program, which provides SBIR and STTR Phase I awardees with a free comprehensive market analysis report that can help jump start commercialization efforts for small businesses. STTR awardees are now eligible to participate in this program. Applications are accepted on a first-come, first-served basis until all 125 slots are filled. Click here to learn more about the Niche Assessment Program and to access the application.
  • NCI Clinical Assay Development Program (CADP): The NCI CADP is requesting project applications from investigators seeking clinical assay validation resources that are designed to assist with the development of assays that may predict therapy response or prognostic behavior of a diagnosed cancer, primarily for use in clinical trials. For more information on the CADP or to submit an application, please visit: http://cadp.cancer.gov/. Please note that this call for applications is not a solicitation for biomarker discovery and is not a grants program. The next deadline to apply for the CADP is October 15, 2012.

If you are interested in discussing your organization’s project with NCI Development Center staff to explore how it aligns with NCI’s priorities, please contact a Program Director at ncisbir@mail.nih.gov. To learn more about the NCI SBIR Development Center, please visit: http://sbir.cancer.gov/index.asp.

View a complete list of all funding opportunities available from the NCI SBIR & STTR Programs.

The SBIR & STTR Programs are NCI’s engine of innovation for developing and commercializing novel technologies and products to prevent, diagnose, and treat cancer. The SBIR & STTR Programs are government set-aside programs for domestic small businesses to engage in research and development that has the potential for commercialization and public benefit.

Sign up to receive updates about
SBIR & STTR funding opportunities at
sbir.cancer.gov

Advertisements

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s


%d bloggers like this: